cas 98946-18-0|| where to buy tert-Butyl trichloroacetimidate

Produktname:tert-Butyl trichloroacetimidate

IUPAC Name:tert-butyl 2,2,2-trichloroethanimidate

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge
CM256074-500g	in stock	ȺǊư

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 98946-18-0 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:98946-18-0; Molekulare Formel:C6H10Cl3NO; Schmelzpunkt:-; SMILES-Code:CC(OC(C(Cl)(Cl)Cl)=N)(C)C; Dichte:

: Katalognummer:CM256074; Molekulargewicht:218.5; Siedepunkt:183.3°C at 760 mmHg; Mdl-Nr.:MFCD00077410; Lagerung:Keep in a tight container and store at below -20°C

: Aliphatic Chain Compounds; Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

: Vepdegestrant; Arvinas and Pfizer updated clinical data from a Phase 1b combination cohort evaluating vepdegestrant in combination with palbociclib. These data show that vepdegestrant plus palbociclib continue to demonstrate encouraging clinical activity in heavily pre-treated patients with a median of four lines of prior therapy with locally advanced or metastatic ER positive/human epidermal growth factor 2 – HER2 – negative breast cancer. Vepdegestrant is an investigational PROTAC ER degrader designed to harness the body’s natural protein disposal system to specifically target and degrade the estrogen receptor.